Kolexia
Thiebaut Rodolphe Santé publique
Thiebaut Rodolphe
Santé publique
Hôpital Pellegrin
Bordeaux, France
315 Activités
2.7 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Infections à VIH COVID-19 Fièvre hémorragique à virus Ebola Maladies virales Fièvre Séropositivité VIH Infections à cytomégalovirus Inflammation Maladies transmissibles

Collaborateurs

Voir plus
Richert Laura
Richert Laura
Hôpital Pellegrin, Bordeaux, France
Levy Yves
Levy Yves
Hôpital Henri Mondor, Créteil, France
Chene Genevieve
Chene Genevieve
Hôpital Pellegrin, Bordeaux, France
Dabis Francois
Dabis Francois
CHU Bordeaux, Bordeaux, France

Industries

Voir plus
{{person.topindus1.name}}
{{person.topindus1.tot}} collaboration(s)
Dernière en {{person.topindus1.last}}
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Redefining pandemic preparedness: Multidisciplinary insights from the CERP modelling workshop in infectious diseases, workshop report.
Infectious Disease Modelling   23 février 2024
Estimating the population effectiveness of interventions against COVID-19 in France: A modelling study.
Epidemics   02 février 2024
PNAS: Study of the Neutralizing Power of Anti-SARS-CoV-2 (Anti-COVID-19) Serum Antibodies
Essai Clinique (Centre Hospitalier Régional D'Orléans Hôpital de La Source)   08 janvier 2024
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
NPJ vaccines   08 novembre 2023
Enriching single-arm clinical trials with external controls: possibilities and pitfalls.
Blood advances   26 octobre 2023
Doubly robust evaluation of high-dimensional surrogate markers.
Biostatistics (Oxford, England)   23 octobre 2023
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
The Lancet. Global health   23 octobre 2023
A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants: A Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Heterologous 2-dose Vaccination Regimen Using Ad26.ZEBOV and MVA-BN®-Filo in Infants Aged 4-11 Months in Guinea and Sierra Leone
Essai Clinique (Janssen)   11 octobre 2023
Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo.
Cell reports   08 septembre 2023
Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2.
PLoS computational biology   07 août 2023